AnaptysBio, Inc. (ANAB) Shares Bought by Teachers Advisors LLC
Teachers Advisors LLC boosted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 23.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,520 shares of the biotechnology company’s stock after buying an additional 1,807 shares during the period. Teachers Advisors LLC’s holdings in AnaptysBio were worth $228,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its position in AnaptysBio by 94.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after buying an additional 9,414 shares during the period. Swiss National Bank acquired a new position in AnaptysBio during the second quarter worth approximately $242,000. Bank of New York Mellon Corp increased its position in AnaptysBio by 46.8% during the second quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock worth $473,000 after buying an additional 6,297 shares during the period. Geode Capital Management LLC acquired a new position in AnaptysBio during the first quarter worth approximately $1,522,000. Finally, TIAA CREF Investment Management LLC acquired a new position in AnaptysBio during the first quarter worth approximately $227,000. 73.05% of the stock is currently owned by institutional investors.
A number of research analysts have recently issued reports on the company. Wedbush reissued a “positive” rating and issued a $82.00 target price (up previously from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Tuesday, August 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 target price on shares of AnaptysBio in a report on Tuesday, September 12th. SunTrust Banks, Inc. assumed coverage on AnaptysBio in a report on Wednesday, November 15th. They issued a “buy” rating and a $115.00 target price on the stock. Finally, Robert W. Baird set a $69.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. AnaptysBio currently has a consensus rating of “Buy” and a consensus price target of $84.78.
ILLEGAL ACTIVITY NOTICE: “AnaptysBio, Inc. (ANAB) Shares Bought by Teachers Advisors LLC” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/anaptysbio-inc-anab-shares-bought-by-teachers-advisors-llc/1718944.html.
Shares of AnaptysBio, Inc. (ANAB) opened at $79.23 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. AnaptysBio, Inc. has a 12 month low of $15.17 and a 12 month high of $79.45.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. equities analysts predict that AnaptysBio, Inc. will post -1.72 EPS for the current year.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.